Sangamo And Biogen Tie Up, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
Nevro Corp. (NVRO)
Last nevro corp. earnings: 2/25 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
nevro.com/english/investors/overview/default.aspx
Company Research
Source: Seeking Alpha
SummarySangamo and Biogen initiated a global licensing deal.AstraZeneca received FDA approval for Selumetinib.Boston Scientific lost a patent lawsuit.Sangamo Closes Gene Collaboration with BiogenSangamo Therapeutics (SGMOreportedBIIBUnder the terms and conditions of the collaboration, Sangamo has received $225 million in funds and is entitled to receive further upfront license fee of $125 million. The latter payment will be due no later than May 8, 2020. Sanagmo also stands to earn up to $2.37 billion in different commercial, regulatory and development milestone payments. This sum includes up to $1.445 billion in first commercial sale and other sales related milestone payments and up to $925 million in pre-approval milestone payments. Apart from these payouts, Sangamo is also entitled to receive staggered high single-digit to sub-teen double-digit royalties on sales of products coming out of this collaboration.Sangamo stated that the collaboration is a testimony to its commitment to g
Show less
Read more
Impact Snapshot
Event Time:
NVRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVRO alerts
High impacting Nevro Corp. news events
Weekly update
A roundup of the hottest topics
NVRO
News
- Cellino Hosts Second Annual Personalized RegenMed Forum to Accelerate Progress in Regenerative Medicine [Yahoo! Finance]Yahoo! Finance
- Nevro Corp. (NYSE: NVRO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- NVRO Stock Declines Despite Positive Study Data of Nevro1 System [Yahoo! Finance]Yahoo! Finance
- New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches [Yahoo! Finance]Yahoo! Finance
- New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral ApproachesPR Newswire
NVRO
Earnings
- 11/11/24 - Beat
NVRO
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- NVRO's page on the SEC website